Ruthenium-106 Plaque Brachytherapy in Patients with Recurrent Ocular Surface Squamous Neoplasia

To assess the results of brachytherapy with ruthenium-106 in patients with recurrent ocular surface squamous neoplasia. In this retrospective study, 3 eyes of 3 patients with recurrent ocular surface squamous neoplasia underwent brachytherapy of one eye with ruthenium-106 (RU-106) plaques. The mean age of patients was 66 years. The maximum diameter of the tumor was 11 mm and the median thickness was 2 mm, the follow-up period was an average of 14 months. In all four eyes, recurrent neoplasia of the squamous cell or cornea completely receded. None of the patients showed clinical and paraclinical evidence of tumor invasion of the eye. Distant metastases were not observed in any of the patients. Brachytherapy with RU-106 plaque is an alternative method for treatment of selected patients with recurrent ocular surface squamous neoplasia.